Headquarters: Oxford, United Kingdom
Founded: 2010
Website: brainomix.com
Brainomix is a medical AI company specializing in imaging software for stroke and neurological conditions. The company's flagship product, e-Stroke, uses artificial intelligence to analyze CT and MRI brain scans and help clinicians make faster, more accurate treatment decisions. Brainomix technology is deployed in over 500 hospitals worldwide and has analyzed millions of scans.
| Attribute |
Details |
| Headquarters |
Oxford, United Kingdom |
| Founded |
2010 |
| Focus |
AI-powered medical imaging |
| Products |
e-Stroke platform |
| Hospitals |
500+ worldwide |
| Scans Analyzed |
Millions |
| Product |
Modality |
Indication |
Status |
| e-Stroke |
CT/MRI |
Acute stroke assessment |
Commercial |
| e-CTP |
CT Perfusion |
Penumbra imaging |
Commercial |
| e-MRI |
MRI |
Diffusion-weighted imaging |
Commercial |
| e-Vessel |
CTA/MRA |
Vessel analysis |
Commercial |
The e-Stroke platform provides comprehensive stroke imaging analysis:
- Automated ASPECTS Scoring: Quantitative assessment of early ischemic changes using Alberta Stroke Program Early CT Score
- Core-Penumbra Mismatch: Identification of salvageable brain tissue to determine treatment eligibility
- Large Vessel Occlusion (LVO) Detection: Automatic identification of vessel occlusions
- Volume Quantification: Precise measurement of infarct core and penumbra
- Treatment Recommendations: Evidence-based guidance for thrombolysis and thrombectomy
CT Perfusion imaging for advanced stroke assessment:
- Cerebral blood flow (CBF) mapping
- Cerebral blood volume (CBV) measurement
- Mean transit time (MTT) analysis
- Automated penumbra identification
MRI-based stroke assessment:
- Diffusion-weighted imaging (DWI) analysis
- Fluid-attenuated inversion recovery (FLAIR) assessment
- Apparent diffusion coefficient (ADC) mapping
¶ AI and Machine Learning
Brainomix's AI algorithms are trained on millions of annotated images:
- Deep learning models for image segmentation
- Transfer learning from large medical imaging datasets
- Continuous algorithm improvement through clinical feedback
The platform provides:
- Automated ASPECTS Scoring: Quantitative assessment of early ischemic changes
- Core-Penumbra Mismatch: Identification of salvageable brain tissue
- Vessel Occlusion Detection: Automatic large vessel occlusion identification
- Volume Calculations: Precise measurements for treatment planning
- Time Savings: Rapid analysis (<2 minutes) vs. manual review (15-20 minutes)
Multiple peer-reviewed studies have validated Brainomix technology:
| Study |
Finding |
Impact |
| AI-Automated CT Perfusion (2021) |
Reduced door-to-treatment time by 30+ minutes |
Faster treatment decisions |
| Clinical Impact of AI Stroke Imaging (2022) |
Improved patient outcomes in endovascular therapy |
Better clinical outcomes |
| Extended Window Analysis (2023) |
Extended treatment window efficacy validation |
Expanded treatment eligibility |
- Time savings: 30+ minute reduction in door-to-treatment time
- Accuracy: High correlation with expert radiologist assessments
- Consistency: Standardized analysis across institutions
- Outcomes: Improved functional outcomes in treated patients
- Workflow: Streamlined imaging triage
While primarily focused on acute stroke, Brainomix technology has significant potential applications in neurodegeneration:
- Cerebral small vessel disease: Quantification of white matter hyperintensities
- Vascular burden assessment: Total small vessel disease load scoring
- Stroke recurrence risk: Identification of high-risk vascular patterns
- Treatment monitoring: Assessment of vascular interventions
- Neuroimaging biomarkers: Amyloid and tau imaging analysis
- Brain volume tracking: Hippocampal atrophy measurement
- White matter changes: Leukoaraiosis assessment
- Vascular contribution: Mixed pathology identification
- Vascular parkinsonism: Differentiation from idiopathic PD
- White matter involvement: Assessment of vascular burden
- Neuroimaging biomarkers: DaTscan analysis support
- White matter hyperintensities: Automated segmentation and grading
- Lacunes: Detection and counting
- Microbleeds: Susceptibility-weighted imaging analysis
- Perivascular spaces: Assessment of perivascular space enlargement
Brainomix is a leading player in the stroke imaging AI space:
- Competitors: Viz.ai, RapidAI, Zebra Medical Vision
- Differentiation: Specialized stroke focus, European market strength
- Partnerships: Major hospital networks, stroke systems of care
- Neurodegenerative disease imaging
- International market expansion
- Integration with EHR systems
- Tele-neuroradiology support
- FDA: Cleared for clinical use in US
- CE Mark: Approved for European market
- UK NHS: Adopted across NHS stroke networks